Probio Naturprodukte offers dietary supplements and nutraceuticals. The products are marketed as made with natural ingredients aimed at supporting health and beauty. Some claims are self-described.

Probio Naturprodukte

ProBio | 16,909 followers on LinkedIn. Manufacturing Life-Changing Therapies | ProBio is a global contract development and manufacturing (CDMO) organization, which aims to accelerate the manufacturing of life-changing drugs, discover novel therapeutic targets, and develop innovative therapeutic approaches to manufacture best-in-class DNA, RNA, and protein-based therapeutics. As a global partner, ProBio brings together multi-disciplinary expertise to accelerate the manufacturing of advanced therapies, including biologics, protein and mRNA vaccines, viral vectors, antibody-drug conjugates and drug discovery services. We aid you in realizing the potential of your breakthrough discovery to treat diseases and improve lives.

Director Of Business Development @ GenScript ProBio | Biologics development and GMP manufacturing Expert, Cell & Gene Therapy

Roman Safonov

Sr. Manufacturing Manager, Downstream

Nicholas Contessa

BD Executive II, GenScript ProBio (CDMO services, biologics/plasmid/virus GMP manufacturing)

Fei (Fay) Guan

SVP, CMC at Third Arc Bio

Arvind Srivastava, Ph.D.

ProBio

We are Rome-bound for ESGCT 2024! 🚀Ready to bring your therapy to market? Let's partner and make it happen! Meet Brahim Gargouri, Ph. D. , Max Maletta , Qingyu C. , Payal Roychoudhury, André Fernandes , Jessica Tu at European Society of Gene and Cell Therapy 2024! Discover our expanded gene & cell therapy manufacturing capabilities: ✅ Cell therapy - CAR #binder development ( #scFv , #VHH , #sdAb ) ✅ Plasmid #DNA production ✅ Viral vector manufacturing ( #AAV , #LVV , #RV , #OV ) Our track record: 🧬 400+ batches manufactured 📊 26+ cell therapy INDs supported Come to our booth to explore how we can accelerate your therapy's journey from ideas to patients! 🧬💡

Congratulations to LaNova Medicines ’s team! #IO #PD1 #VGEF #cancer #bispecificantibody #bsab #immunooncology

Meet Whitney Winters at the Terrapinn 's Advanced Therapies USA in Philadelphia! Let's discuss how ProBio can help streamline your cell and gene therapy development process and expedite your path to market.

Less than two weeks left! Join us at the GenScript Biotech Global Forum in London on Wednesday, November 20, 2024! ProBio is honored to welcome leading experts in cell and gene therapy, biotechnology, and regulatory affairs to explore the theme ‘CMC Challenges with Developing & Manufacturing Cell and Gene Therapies.’ We will delve into the complexities of CMC (Chemistry, Manufacturing, and Controls) in #CGT , covering key topics such as early market access, manufacturing solutions, and sustainable processes. Don’t miss this opportunity to connect and discuss how we can help accelerate your pipeline! For registration, please visit at https://lnkd.in/eH62cyym #biotechglobalforum #celltherapy #genetherapy #probio #cgt

At ProBio , we are proud to support the professional growth and development of our talented team members like Josh Coughlin. His dedication to quality and excellence embodies our commitment to delivering industry-leading solutions in the biotech and pharmaceutical sectors. As we continue to expand our operations in Hopewell, NJ, we remain focused on fostering a culture of innovation, reliability, and continuous improvement. Together, we’re shaping the future of next generation medicine.

ProBio is proud to support its partner Chengdu Chimagen Biosciences Co., Ltd (Chimagen), in a landmark strategic agreement with pharmaceutical leader GlaxoSmithKline (GSK). This collaboration includes GSK’s acquisition of Chimagen’s clinical-stage trispecific antibody, #CMG1A46 , with an initial payment of $300 million and potential milestone payments totaling up to $550 million, contigent upon successful development and commercialization. ProBio has provided comprehensive preclinical #CMC services to support the advancement of this innovative therapy, which represents a major breakthrough in trispecific antibody therapeutics. The CMG1A46 antibody uniquely targets CD3, CD19, and CD20, demonstrating efficacy in the elimination of B cells and showing potential for treating autoimmune diseases such as systemic lupus erythematosus (SLE) and lupus nephritis (LN). Notably, this is the first CD3/CD19/CD20 trispecific antibody to enter clinical trials, exhibiting promise for treating resistant and relapsed B-cell blood cancers. Dr. Li Chen, CEO of ProBio, shared her enthusiasm: “We congratulate Chimagen on this significant milestone. Our shared vision for multispecific antibody innovation aligns perfectly, and we’re excited to accelerate the progress of CMG1A46 to bring more effective therapeutic options to patients worldwide.” This partnership highlights ProBio’s expertise in enabling the global development of groundbreaking therapies and reinforces its reputation as a trusted collaborator in the biotech market. For more information about the expansion and how to collaborate with ProBio, please visit www.probiocdmo.com

Meet our team at the GenScript Biotech Global Forum London 2024 on Wednesday, November 20! Under the theme ‘CMC Challenges with Developing & Manufacturing Cell and Gene Therapies’, ProBio is proud to invite thought leaders in cell and gene therapy, biotechnology, and regulatory affairs to address complexities of CMC (Chemistry, Manufacturing, and Controls) in the development and production of cell and gene therapies, with a focus on ensuring early market access, overcoming manufacturing challenges, and promoting sustainable processes. We are excited to discuss how to advance your pipeline in #CGT ! See you there! For registration, please visit at https://lnkd.in/eH62cyym #biotechglobalforum #celltherapy #genetherapy #probio #gct

Meet our team at PEGS 2024 on 5th to 7th November, renowned as "the best biologics technology meeting in Europe"! Visit our booth at 1218 to discuss how our #biologics services, including protein and antibody drug, bsAb, and ADC discovery, can advance your pipeline. We would be happy to share valuable CDMO insights that can drive your projects forward! Schedule 1-on-1 meeting with us: https://lnkd.in/e-Vra3ft #PEGS #biologics #probio #PAD #ADD

Can’t wait to see you at Bio Europe Fall 2024 on 4th to 6th November! As Europe's leading partnering event, this event provides an exceptional opportunity to connect with more potential partners in just three days than you could throughout the entire year. Visit our booth at 193 and explore how our #biologics and #CGT services, including GMP plasmid, mRNA, ADC discovery, can advance your pipeline. See you there! Schedule 1-on-1 meeting with us: https://lnkd.in/ehAfcZSb #bioeurope #BIO #biologics #CGT #probio

Join us at the upcoming GenScript Biotech Global Forum London 2024 on Wednesday, November 20! We are excited to share our extensive capabilities in #CGT services. #biotechglobalforum #probio #gct #celltherapy #genetherapy

Metric
Company Name	Probio Naturprodukte
Symbol
MSH ID	ONE:PROBIO
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Health and Wellness
Country	DE
Stage	Series C
Employee Count
Website	probio.one
LinkedIn	probio-cdmo
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	25.50K
Web Traffic Growth	5.36
Valuation
Raised Capital	220M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

PROB

ONE:PROBIO

Probio Naturprodukte

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue